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Background: The number of people with diabetes is increasing worldwide, especially in developing South Asian
countries. Therefore, preventing diabetes at the early stages has become an important issue. Recent clinical trials,
systematic reviews, and meta-analysis have shown that zinc has beneficial effects on glycemic and metabolic
control in those with diabetes. The present study is designed to evaluate the effects of zinc supplementation on
glycemic control and other metabolic parameters in those with pre-diabetes.
Methods/design: The study will be conducted as a randomized, double-blind, placebo-controlled clinical trial for a
period of 12 months at the Faculty of Medicine, University of Colombo, Sri Lanka. The study has been approved by
the Ethics Review Committee of Faculty of Medicine, University of Colombo (EC/11/189). A total of 200 adults (age
18–60 years) with pre-diabetes will be recruited for the study. They will be stratified according to age, gender, and
body mass index and randomly assigned into the test and placebo groups on a 1:1 ratio. The zinc capsules, each
weighing 456 mg, will contain the following ingredients:zinc sulfate monohydrate 55.096 mg (elemental zinc 20
mg), lactose monohydrate 399.504 mg, and stearic acid 1.400 mg. The placebo capsule with the same weight will
be comprised of lactose monohydrate 454.600 mg and stearic acid 1.400 mg. The subjects will receive either zinc
20 mg capsules or placebo daily for a period of 12 months. The study drugs will be double blinded to both
investigators and subjects. The visits and the evaluations will be done as follows: screening (visit 0), 1 month (visit
1), 3 month (visit 2), 6 month (visit 3), and 12 month (visit 4). The following primary outcome measures will be
evaluated:fasting plasma glucose (FPG), post oral glucose tolerance test (OGTT), serum insulin, HbA1c, total/low-
density lipoprotein (LDL)/high-density lipoprotein (HDL) cholesterol, triglycerides, serum zinc, and appetite using a
visual analog scale. Secondary outcome measures include: blood pressure, anthropometry, and dietary assessment
using a validated food frequency questionnaire. Data will be analyzed using SPSS v16.
Discussion: The present protocol will aim to establish the beneficial effects of zinc supplementation on disease
progression in those with pre-diabetes and also establish its effectiveness in the prevention of diabetes mellitus.
Trial registration: Sri Lanka Clinical Trial Registry: SLCTR/2012/010
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The prevalence of diabetes and pre-diabetes is increasing
worldwide because of population growth, aging, urbanization,
and increasing prevalence of obesity and physical inactivity.
The South Asian region is currently experiencing an epidemic
of diabetes and its associated complications [1,2]. The
projected increase in prevalence of diabetes is out of propor-
tion to the estimated increase in population [3]. In 1990, the
prevalence of diabetes in Sri Lanka was 2.5%; however, most
recent studies show more than 1/5 of Sri Lankan adults are
dysglycemic [4,5]. The prevalence of diabetes and pre-
diabetes in the Sri Lankan adult population in 2005–2006
was 10.3% and 11.5% respectively [5]. Studies from developed
countries have shown that the direct cost involved in the
treatment of diabetes and its associated complications are
high [6]. Furthermore the indirect costs due to early mortality,
morbidity, and loss of productivity are likely to be much
higher. This is even more pronounced in developing coun-
tries of the South Asian region, which are faced with the
highest burden of disease [1]. Therefore, simple and effective
preventive measures for those at risk of developing diabetes
are a timely requirement.
Insulin is stored in β-cells of the pancreas in granules
that contains a variable number of zinc atoms. Studies
have shown that zinc plays an important role in insulin
synthesis, storage, secretion, and action, while also being
involved in various stages of carbohydrate and protein me-
tabolism [7,8]. Oxidative stress plays an important role in
the pathogenesis of diabetes and its complications.
Impaired synthesis of antioxidant enzymes, such as super-
oxide dismutase and glutathione peroxidase, may be
associated with increased oxidative stress [9]. Zinc is an
integral structural component of these antioxidant
enzymes, and zinc deficiency may impair their synthesis.
In-vitro studies in animal models and in humans have
demonstrated that zinc supplementation improves gly-
cemic control and other metabolic parameters in diabetes
[10-13]. A recent systematic review and meta-analysis on
the effects of zinc supplementation in patients with dia-
betes showed that zinc supplementation reduces blood
glucose, total cholesterol, and LDL cholesterol while im-
proving glycemic control as demonstrated by a reduction
in HbA1c [14]. Zinc supplementation has also shown
beneficial effects on insulin resistance and components of
the metabolic syndrome in pre-pubertal obese children
[15]. However, at present there are no studies evaluating
the long-term effects of zinc supplementation in preven-
tion of disease in those at risk of diabetes. The present
study aims to evaluate the effects of zinc supplementation
on the progression of disease in patients with pre-diabetes
from Sri Lanka and determine the metabolic effects of
zinc supplementation on glycemic control. In addition, we
also aim to evaluate effect of zinc supplementation on
body weight and appetite in those with pre-diabetes.Methods/design
Objectives and hypothesis
Objectives: The study aims to evaluate the effects of zinc
supplementation on the progression of disease in
patients with pre-diabetes from Sri Lanka and determine
the metabolic effects of zinc supplementation on gly-
cemic control. Furthermore, we aim to evaluate the
effects of zinc supplementation on appetite and body
weight in patients with pre-diabetes.
Hypothesis: The glucose concentration of pre-diabetic
patients who are treated with elemental zinc 20 mg daily
will be lower than that of the control group. We also
hypothesize that other diabetes-related metabolic parameters
(serum insulin, total cholesterol, triglyceride, HDL choles-
terol, LDL cholesterol, and blood pressure) will be improved
in the treatment group in comparison to the control
group.
Study design
The study will be conducted as a randomized, double-
blind, placebo-controlled clinical trial for a period of 12
months to assess the efficacy of daily zinc 20 mg supple-
mentation in pre-diabetes. The study will be conducted
at the Faculty of Medicine, University of Colombo, Sri
Lanka. Figure 1 provides an overview of the study.
Sample size
The number of patients required for determination of a
20% reduction of fasting plasma glucose in the treatment
arm in comparison with the placebo arm at 90% power
and 95% confidence interval with a dropout rate of 30%
is 100 patients per arm. Hence, a total of 200 subjects
with pre-diabetes will be recruited for the study.
Population
Pre-diabetes is defined as the presence of fasting plasma
glucose levels between 110–125 mg/dl or 2-hpost-oral
glucose plasma glucose levels between 140–199 mg/dl
or both [World Health Organisation (WHO) 2006 cri-
teria] [16]. Study participants will be recruited for the
study after obtaining informed written consent.
Inclusion and exclusion criteria
Inclusion criteria
 Both genders between the ages of 18–60 years, eligible
for study through a screening test confirming the
presence of pre-diabetes as defined above.
Exclusion criteria
 On any other vitamin or mineral supplementations
or the current use of a weight loss medicine or
dietary modification.




(456mg capsules, 1 capsule/day 
for 12 months) 
Placebo group 
(456mg capsules, 1 capsule/day 
for 12 months) 
Clinical and biochemical measurements 
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Visit ‘4’ (12 month) 
Figure 1 Schematic representation of study design.






USP 55.096 mg Active
ingredient
Lactose monohydrate BP 399.504 mg Filler
Stearic acid USP 1.400 mg Lubricant
Total weight 456.00 mg
*Contains 20 mg of elemental zinc.
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 Alcohol consumption > 20 g/day.
 Presently having acute diseases or other untreated
illness requiring treatment.
 Impaired hepatic or renal functions.
 Lactation, pregnancy or unwillingness to use an
effective form of birth control for women of child-
bearing years.
 History or presence of any condition, in the
investigator’s opinion, that would endanger the
individual’s safety or affect the study result.
Suspension criteria
 Subject’s demand to discontinue the study.
 Serious adverse events or unusual changes in clinical
test results.
 Principal investigator’s decision to terminate the
study (low rates of compliance, complications, or
unable to sustain the study for various reasons).
Randomization
Subjects will be stratified according to age, gender, and
body mass index and randomly assigned into the test
and placebo groups at a 1:1 ratio according to the ‘ran-
dom number table’ generated by SPSS v16.0 software
package (SPSS Inc., Chicago, IL, USA).
Blinding
The study drugs are double blinded to both investigator
and subject. The drug manufacturing will be done by
SAP enterprises (PVT) Ltd., Colombo, Sri Lanka, andthey will be responsible for the labeling of the zinc cap-
sule and placebo with code numbers.
Interventions
The treatment drug is a capsule containing elemental
zinc 20 mg as the active ingredient; it will have a white-
colored body and a cap. The constituents of the zinc
capsule are summarized in Table 1. The placebo capsule
will contain lactose monohydrate (454.600 mg) and ste-
aric acid (1.400 mg). The placebo will be manufactured
to have a similar appearance, shape, weight, taste, and
color as thezinc 20 mg capsule. The subjects will receive
either one capsule of 20 mg zinc or an identical placebo
daily, taken 1 h before breakfast for a period of 12
months.
Study groups
a. Treatment group: zinc capsule
b. Control group: placebo
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The study will be conducted for a period of 12 months.
The visits and the evaluations will be done as follows:
screening (visit 0), 1 month (visit 1), 3 month (visit 2), 6
month (visit 3), and 12 month (visit 4).
Outcomes
Primary outcome index: The following biochemical
assessments will be done at baseline, at the stated
intervals, and on completion: FPG, OGTT, serum insu-
lin, HbA1c, total cholesterol, triglycerides, LDL choles-
terol, HDL cholesterol, and serum zinc. Furthermore,
appetite will be evaluated using the visual analog scale
(VAS).
Secondary outcome index:
a. Measurement of systolic (SBP) and diastolic blood
pressure (DBP).
b.Anthropometric assessment such as body weight,
height, body mass index (BMI), waist circumference
(WC), hip circumference (HC), and waist: hip ratio
(WHR).
c. Dietary assessment using a validated food frequency
questionnaire (FFQ) [17].
The primary and secondary outcomes will be
measured at the screening visit (visit 0), 1-month visit
(visit 1), 3-month visit (visit 2), 6-month visit (visit 3),
and 12-month visit (visit 4). The changes between visit 0Table 2 A brief study schedule at every visit
Visit 0 (screening visit) Visit 1 (1 mo
Informed consent form •
Recording demographic data •
Medical history taking •
Physical examination1 • •
FPG • •
OGTT • •
Serum insulin • •
Lipid profile2 • •
HbA1c • •




Blood pressure • •
Electrocardiogram •
Food frequency questionnaire • •
Appetite (VAS) • •
1Body weight, height, waist circumference and hip circumference; 2total cholesterol
bilirubin, albumin, and total protein; 4creatinine and blood urea nitrogen (BUN); 5Wand visit 4 measurements will be analyzed for the pri-
mary outcome indexes.
Safety assessment index: The following information
will be recorded/measured for the safety assessment:
vital signs, general medical examinations, full blood
count (FBC), renal function test, liver function test, and
adverse events. Liver profile, renal profile, and FBC will
be done at the screening day (visit 0), after 6 months
(visit 3), and at the end of the study (visit 4). All other
assessments will be done at each of the four visits.
Procedures
Recruitment
Participants will be recruited by open advertisement in
newspapers, online, and notice boards at hospitals.
Those who see the trial poster will visit the trial site
voluntarily.
Study schedule
The detailed items that will be measured at every visit
are described in Table 2.
Measurement tools
Anthropometric measurements
Body weight will be measured using a calibrated elec-
tronic floor scale (SECA 815 by SECA GmbH & Co. Kg.,
Hamburg, Germany) to the nearest 0.1 kg. Height will
be measured to the nearest 0.1 cm using an upright plas-















, triglyceride, LDL cholesterol, and HDL cholesterol; 3AST, ALT, g-GTP, total
BC, RBC, hemoglobin (Hb), hematocrit, and platelet count.
Ranasinghe et al. Trials 2013, 14:52 Page 5 of 6
http://www.trialsjournal.com/content/14/1/52Co. Kg., Hamburg, Germany). BMI will be calculated as
weight (in kilograms) divided by the square of height (in
meters). Waist circumference (WC) will be measured
with a non-elastic tape (SECA 203 by SECA GmbH &
Co. Kg., Hamburg, Germany) at a point midway be-
tween the lower border of the rib cage and the iliac
crest at the end of normal expiration. Similarly, the hip
circumference also will be measured at the widest part
of the buttocks atthe intertrochanteric level to the
nearest 0.1 cm. All anthropometric measurements will
be made by using standard equipment and following
WHO guidelines.
Dietary measurements
A culturally validated FFQ will be used to obtain habit-
ual intake of calorie, macro- and micronutrients [17]. A
VAS, 10 cm in length with words anchored at each end,
expressing the most positive and the most negative rat-
ing, will be used to assess hunger, satiety, fullness, and
desire to eat.
Compliance calculation
Subjects are asked to return remaining drugs and their
compliance will be evaluated by using the formula given
below:





Parametric and nonparametric statistical tests will be ap-
plied using SPSS version 16 (SPSS Inc., Chicago, IL,
USA) and Stata/SE 10.0 (StataCorp., College Station, TX,
USA) for the data analysis. For each of the outcomes,
multilevel regression analysis will be used to examine
differences between trial arms. For binary outcomes the
model will be logistic and for continuous outcomes the
model will be linear regression. All analyses will follow
intention-to-treat principles and a pre-specified analysis
plan. Where appropriate, sensitivity analyses will be
conducted (for example, control for additional covariates
and bootstrapped p values for skewed outcomes). In the
case of missing data values, we will apply mean imput-
ation and regression imputation where rates are low and
consider multiple imputations where they exceed 10%.
Adverse effect evaluation
The Recommended Daily Allowance (RDA) of zinc is 11
mg in adult males and 8 mg in females [18]. In addition,
it has been shown that the therapeutic window for zinc
is between 9–40 mg. Hence, 20 mg of elemental zinc is
a safe dose for humans. However, in the event of aprobable adverse reaction, the following precautions
would ensure timely identification and management of
patients:
 Reporting mechanisms will be put in place to ensure
direct reporting of probable adverse events to the
investigator by patients (via telephone, which will be
available 24 h on all days).
 During follow-up visits, probable adverse events will
be noted by history and examination and
investigated in detail. All adverse effects observed
will be documented in the case record form (CRF)
(Additional file 1).
 All serious adverse events will be reported to the
Ethics Review Committee, Faculty of Medicine,
University of Colombo, and the National Pharmaco-
vigilance Unit of the Department of Pharmacology,
Faculty of Medicine, University of Colombo.
 A Data Safety Monitoring Board (DSMB) identified
by the investigators will evaluate all the adverse
events at regular intervals
 Investigations including liver function, renal
function, and FBC will be assessed as detailed above.
 Termination of study: In the event of major adverse
effects occurring in a significant proportion of the
study population, the study would be terminated
pending further investigation.
Data collection
Data collection will be performed according to the
standard operating procedures by medically trained re-
search assistants (RAs).
Data and biological sample handling
Data will be entered by a minimum number of dedicated
staff and saved in a dedicated computer with password
protection. Blood samples will be stored in a secure fa-
cility with redundant measures to ensure specimens are
kept in compliant conditions at all times when in storage.
Storage technologies with the capability of monitoring the
temperature of samples around the clock will be utilized.
After each analysis has been completed and with the ap-
proval of the principal investigator, the samples stored in
the storage facility may be disposed of by the sample cus-
todian. Asample disposal sheet (SDS) will be completed
and kept for further reference.
Ethical approvals
The study has been approved by the Ethics Review Com-
mittee (ERC) of the Faculty of Medicine, University of
Colombo (EC/11/189). The trial is also registered at the
Sri Lanka Clinical Trials Registry (SLCTR/2012/010).
The study will be conducted in compliance with the
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(GCP) guidelines.
Discussion
In this article, we present a clinical trial design to evalu-
ate the effects of zinc supplementation in those with
pre-diabetes. To our knowledge this is one of the first
randomized controlled trials evaluating the effects of
long-term zinc supplementation in pre-diabetes. This
study will provide the necessary groundwork for future
large-scale multicenter clinical trials. Given the current
enthusiasm for using various dietary supplements to im-
prove glycemic control and metabolic parameters in
those with dysglycemia, properly designed scientific
evaluations are a timely requirement. Furthermore, in
animal models and in humans, zinc plays an important
role in the regulation of appetite [19]. However, presently
there are no well-designed randomized control trials to
support/refute this argument. This study will also help to
provide information pertaining to appetite changes
resulting from zinc supplementation. Appetite regulation
could be one of the probable mechanisms responsible for
beneficial effects on glycemic control. The result, positive
or negative, should provide a step change in the evidence
guiding current and future policies regarding dietary sup-




Additional file 1: Case Record Form (CRF).
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